Euretina highlights

Article

The 9th Euretina Congress took place during May in Nice, France and was attended, according to the organisers, by around 1700 delegates. This was a seminal event and will be the last of its kind as next year it will join forces with ESCRS (European Society of Cataract and Refractive Surgeons) in Paris from 2–8 September.

The 9th Euretina Congress took place during May in Nice, France and was attended, according to the organisers, by around 1700 delegates. This was a seminal event and will be the last of its kind as next year it will join forces with ESCRS (European Society of Cataract and Refractive Surgeons) in Paris from 2–8 September. The plan is to have separate scientific programmes and two joint symposia.

Across the three and a half days there were nine main sessions, free papers and 19 courses, the latter being well attended across the full three days. However, in talking to both exhibitors and delegates it was apparent that the feeling amongst many is that the number of shows taking place throughout the year is becoming prohibitvely expensive for the former and less attractive to the latter where time is often an issue.

Next year's event will take place in the most expensive exhibition space in the world, namely Paris, at Le Palais de Congres and will represent a considerable investment for all participants. Whilst undoubtedly a huge networking opportunity for doctors as several mentioned to OTEurope: "There are really now too many of these events and a week in Paris is stretching my practice's budget more than a little too far."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.